Glucocorticoids and type 2 diabetes: From physiology to pathology

Journal of Nutrition and Metabolism

Volumn 2012, Issue , 2012, Pages

  Di Dalmazi, Guido ^a   Pagotto, Uberto ^a   Pasquali, Renato ^a   Vicennati, Valentina ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873857427     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2012/525093     Document Type: Review

References (120)

1. Stumvoll M., Goldstein B. J., van Haeften T. W., Type 2 diabetes: principles of pathogenesis and therapy. The Lancet 2005 365 9467 1333 1346 2-s2.0-17044386953 10.1016/S0140-6736(05)61032-X
2. Reaven G. M., Role of insulin resistance in human disease. Diabetes 1988 37 12 1595 1607 2-s2.0-0024160877 (Pubitemid 19004941)
3. Kahn S. E., Hull R. L., Utzschneider K. M., Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006 444 7121 840 846 2-s2.0-33845881411 10.1038/nature05482 (Pubitemid 46024990)
4. Burcelin R., Knauf C., Cani P. D., Pancreatic -cell dysfunction in diabetes. Diabetes and Metabolism 2008 34 supplement 2 S49 S55 2-s2.0-47149095990 10.1016/S1262-3636(08)73395-0 (Pubitemid 351978284)
5. Mulder H., Nagorny C. L. F., Lyssenko V., Groop L., Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia 2009 52 7 1240 1249 2-s2.0-67349224047 10.1007/s00125-009-1359-y
6. Cooper M. S., Stewart P. M., 11 β -hydroxysteroid dehydrogenase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. Journal of Clinical Endocrinology and Metabolism 2009 94 12 4645 4654 10.1210/jc.2009-1412
7. Drucker D. J., Nauck M. A., The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. The Lancet 2006 368 9548 1696 1705 2-s2.0-33846006173 10.1016/S0140-6736(06)69705-5 (Pubitemid 46048557)
8. Boscaro M., Barzon L., Fallo F., Sonino N., Cushing's syndrome. The Lancet 2001 357 9258 783 791 2-s2.0-0035835971 10.1016/S0140-6736(00)04172-6 (Pubitemid 32217692)
9. Connell J. M., Whitworth J. A., Davies D. L., Lever A. F., Richards A. M., Fraser R., Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man. Journal of Hypertension 1987 5 4 425 433 2-s2.0-0023256571 (Pubitemid 17126233)
10. Björntorp P., Holm G., Rosmond R., Hypothalamic arousal, insulin resistance and type 2 diabetes mellitus. Diabetic Medicine 1999 16 5 373 383 2-s2.0-0032706949 10.1046/j.1464-5491.1999.00067.x
11. Charmandari E., Chrousos G. P., Lambrou G. I., Pavlaki A., Koide H., Ng S. S. M., Kino T., Peripheral CLOCK regulates target-tissue glucocorticoid receptor transcriptional activity in a circadian fashion in man. PLoS ONE 2011 6 9 e25612 10.1371/journal.pone.0025612
12. Funder J. W., Glucocorticoid and mineralcorticoid receptors: biology and clinical relevance. Annual Review of Medicine 1997 48 231 240 10.1146/annurev.med.48.1.231 (Pubitemid 27101827)
13. Bamberger C. M., Schulte H. M., Chrousos G. P., Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocrine Reviews 1996 17 3 245 261 2-s2.0-0030026713 10.1210/er.17.3.245 (Pubitemid 26001083)
14. DeRijk R. H., Schaaf M., de Kloet E. R., Glucocorticoid receptor variants: clinical implications. Journal of Steroid Biochemistry and Molecular Biology 2002 81 2 103 122 2-s2.0-0036345304 10.1016/S0960-0760(02)00062-6 (Pubitemid 34879139)
15. Seckl J. R., 11 β -hydroxysteroid dehydrogenases: changing glucocorticoid action. Current Opinion in Pharmacology 2004 4 6 597 602 10.1016/j.coph.2004.09.001 (Pubitemid 40267874)
16. Arnaldi G., Angeli A., Atkinson A. B., Bertagna X., Cavagnini F., Chrousos G. P., Fava G. A., Findling J. W., Gaillard R. C., Grossman A. B., Kola B., Lacroix A., Mancini T., Mantero F., Newell-Price J., Nieman L. K., Sonino N., Vance M. L., Giustina A., Boscaro M., Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism 2003 88 12 5593 5602 2-s2.0-9144250366 10.1210/jc.2003-030871 (Pubitemid 38033020)
17. Barahona M. J., Sucunza N., Resmini E., Fernández-Real J. M., Ricart W., Moreno-Navarrete J. M., Puig T., Wägner A. M., Rodriguez-Espinosa J., Farrerons J., Webb S. M., Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. Journal of Bone and Mineral Research 2009 24 11 1841 1846 2-s2.0-73949142866 10.1359/jbmr.090505
18. Colao A., Pivonello R., Spiezia S., Faggiano A., Ferone D., Filippella M., Marzullo P., Cerbone G., Siciliani M., Lombardi G., Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. Journal of Clinical Endocrinology and Metabolism 1999 84 8 2664 2672 2-s2.0-0033343114 (Pubitemid 30641990)
19. di Somma C., Pivonello R., Loche S., Faggiano A., Marzullo P., di Sarno A., Klain M., Salvatore M., Lombardi G., Colao A., Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clinical Endocrinology 2002 56 2 153 158 2-s2.0-0036129773 10.1046/j.0300-0664.2001.01454.doc.x (Pubitemid 34233953)
20. Dorn L. D., Burgess E. S., Friedman T. C., Dubbert B., Gold P. W., Chrousos G. P., The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism. Journal of Clinical Endocrinology and Metabolism 1997 82 3 912 919 2-s2.0-0031032465 10.1210/jc.82.3.912 (Pubitemid 27106611)
21. Minetto M., Reimondo G., Osella G., Ventura M., Angeli A., Terzolo M., Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporosis International 2004 15 11 855 861 2-s2.0-8644286156 10.1007/s00198-004-1616-3 (Pubitemid 39506451)
22. Newell-Price J., Bertagna X., Grossman A. B., Nieman L. K., Cushing's syndrome. The Lancet 2006 367 9522 1605 1617 2-s2.0-33646340677 10.1016/S0140-6736(06)68699-6 (Pubitemid 43674231)
23. Giraldi F. P., Moro M., Cavagnini F., Gender-related differences in the presentation and course of Cushing's disease. Journal of Clinical Endocrinology and Metabolism 2003 88 4 1554 1558 10.1210/jc.2002-021518 (Pubitemid 36623369)
24. Pivonello R., de Martino M. C., de Leo M., Lombardi G., Colao A., Cushing's syndrome. Endocrinology and Metabolism Clinics of North America 2008 37 1 135 149 2-s2.0-38349144642 10.1016/j.ecl.2007.10.010
25. Sonino N., Fava G. A., Raffi A. R., Boscaro M., Fallo F., Clinical correlates of major depression in Cushing's disease. Psychopathology 1998 31 6 302 306 2-s2.0-0031766744 10.1159/000029054 (Pubitemid 28497657)
26. Sonino N., Fava G. A., Psychiatric disorders associated with Cushing's syndrome: epidemiology, pathophysiology and treatment. CNS Drugs 2001 15 5 361 373 2-s2.0-0034998119 (Pubitemid 32487993)
27. Mancini T., Kola B., Mantero F., Boscaro M., Arnaldi G., High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clinical Endocrinology 2004 61 6 768 777 10.1111/j.1365-2265.2004.02168.x (Pubitemid 40006799)
28. Clayton R. N., Raskauskiene D., Reulen R. C., Jones P. W., Mortality and morbidity in Cushing's disease over 50 Years in Stoke-on-Trent, UK: audit and meta-analysis of literature. Journal of Clinical Endocrinology and Metabolism 2011 96 3 632 642 10.1210/jc.2010-1942
29. Etxabe J., Vazquez J. A., Morbidity and mortality in Cushing's disease: an epidemiological approach. Clinical Endocrinology 1994 40 4 479 484 (Pubitemid 24194645)
30. Hammer G. D., Tyrrell J. B., Lamborn K. R., Applebury C. B., Hannegan E. T., Bell S., Rahl R., Lu A., Wilson C. B., Transsphenoidal microsurgery for Cushing's disease: Initial outcome and long-term results. Journal of Clinical Endocrinology and Metabolism 2004 89 12 6348 6357 10.1210/jc.2003-032180 (Pubitemid 39628458)
31. Dekkers O. M., Biermasz N. R., Pereira A. M., Mortality in patients treated for Cushing's disease is increased, compared with patients treated for non-functioning pituitary macroadenomas. Journal of Clinical Endocrinology and Metabolism 2007 92 976 981 (Pubitemid 46465672)
32. Lindholm J., Juul S., Jørgensen J. O. L., Astrup J., Bjerre P., Feldt-Rasmussen U., Hagen C., Jørgensen J., Kosteljanetz M., Kristensen L., Laurberg P., Schmidt K., Weeke J., Incidence and late prognosis of Cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism 2001 86 1 117 123 2-s2.0-17744362051 10.1210/jc.86.1.117 (Pubitemid 32111743)
33. Bolland M. J., Holdaway I. M., Berkeley J. E., Lim S., Dransfield W. J., Conaglen J. V., Croxson M. S., Gamble G. D., Hunt P. J., Toomath R. J., Mortality and morbidity in Cushing's syndrome in New Zealand. Clinical Endocrinology 2011 75 4 436 442 10.1111/j.1365-2265.2011.04124.x
34. van Raalte D. H., Ouwens D. M., Diamant M., Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options? European Journal of Clinical Investigation 2009 39 2 81 93 2-s2.0-58649095526 10.1111/j.1365-2362.2008.02067.x
35. Seino S., Shibasaki T., Minami K., Pancreatic β -cell signalling: toward better understanding of diabetes and its treatment. Proceedings of the Japan Academy, Series B 2010 86 6 563 577
36. Hansen K. B., Vilsbøll T., Bagger J. I., Holst J. J., Knop F. K., Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. Journal of Clinical Endocrinology and Metabolism 2010 95 7 3309 3317 2-s2.0-77954944284 10.1210/jc.2010-0119
37. Pivonello R., de Leo M., Vitale P., Cozzolino A., Simeoli C., de Martino M. C., Lombardi G., Colao A., Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology 2010 92 supplement 1 77 81 10.1159/000314319
38. Cassuto H., Kochan K., Chakravarty K., Cohen H., Blum B., Olswang Y., Hakimi P., Xu C., Massillon D., Hanson R. W., Reshef L., Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate carboxykinase in the liver via an extended glucocorticoid regulatory unit. The Journal of Biological Chemistry 2005 280 40 33873 33884 10.1074/jbc.M504119200 (Pubitemid 41443107)
39. Patel R., Patel M., Tsai R., LXRb is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. Journal of Clinical Investigation 2011 121 1 431 441 10.1172/JCI41681
40. Rondinone C. M., Adipocyte-derived hormones, cytokines, and mediators. Endocrine 2006 29 1 81 90 2-s2.0-33646873050 10.1385/ENDO:29:1:81 (Pubitemid 43780349)
41. Castan-Laurell I., Dray C., Attané C., Duparc T., Knauf C., Valet P., Apelin, diabetes, and obesity. Endocrine 2011 40 1 1 9 2-s2.0-79959630420 10.1007/s12020-011-9507-9
42. Feelders R. A., Pulgar S. J., Kempel A., Pereira A. M., The burden of Cushing's disease (CD): clinical and health-related quality of life aspects. European Journal of Endocrinology 2012 167 3 311 326 10.1530/EJE-11-1095
43. Mullan K., Black N., Thiraviaraj A., Is there value in routine screening for Cushing's syndrome in patients with diabetes? Journal of Clinical Endocrinology and Metabolism 2010 95 5 2262 2265 10.1210/jc.2009-2453
44. Krarup T., Krarup T., Hagen C., Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome? Diabetes/Metabolism Research and Reviews 2012 28 3 219 227 10.1002/dmrr.2262
45. Burt M. G., Roberts G. W., Aguilar-Loza N. R., Frith P., Stranks S. N., Continuous monitoring of circadian glycemic patterns in patients receiving prednisolone for COPD. Journal of Clinical Endocrinology and Metabolism 2011 96 6 1789 1796 10.1210/jc.2010-2729
46. World Health Organization, Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia: Report of a WHO/IDF Consultation 2006 Geneva, Switzerland World Health Organization
47. American Diabetes Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2011 34 supplement 1 S62 S69 10.2337/dc11-S062
48. Matthews D. R., Hosker J. P., Rudenski A. S., Naylor B. A., Treacher D. F., Turner R. C., Homeostasis model assessment: insulin resistance and β -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 7 412 419 2-s2.0-0021813187 (Pubitemid 15018832)
49. Lansang M. C., Hustak L. K., Glucocorticoid-induced diabetes and adrenal suppression: how to detect and manage them. Cleveland Clinic Journal of Medicine 2011 78 11 748 756 10.3949/ccjm.78a.10180
50. Clore J. N., Thurby-Hay L., Glucocorticoid-induced hyperglycemia. Endocrine Practice 2009 15 5 469 474 2-s2.0-70449721289 10.4158/EP08331.RAR
51. Panthakalam S., Bhatnagar D., Klimiuk P., The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scottish Medical Journal 2004 49 4 139 141 2-s2.0-11344280116 (Pubitemid 40074419)
52. Uzu T., Harada T., Sakaguchi M., Kanasaki M., Isshiki K., Araki S., Sugiomoto T., Koya D., Haneda M., Kashiwagi A., Yamauchi A., Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron-Clinical Practice 2007 105 2 c54 c57 2-s2.0-33846349338 10.1159/000097598 (Pubitemid 46143906)
53. Gurwitz J. H., Bohn R. L., Glynn R. J., Monane M., Mogun H., Avorn J., Glucocorticoids and the risk for initiation of hypoglycemic therapy. Archives of Internal Medicine 1994 154 1 97 101 2-s2.0-0028082371 10.1001/archinte.154.1.97 (Pubitemid 24018107)
54. Davidson J., Wilkinson A., Dantal J., Dotta F., Haller H., Hernández D., Kasiske B. L., Kiberd B., Krentz A., Legendre C., Marchetti P., Markell M., van der Woude F. J., Wheeler D. C., Monaco A. P., Morris P. J., New-onset diabetes after transplantation: 2003 international consensus guidelines-proceedings of an international expert panel meeting Barcelona, Spain 19 February 2003. Transplantation 2003 75 10 SS1 SS24 2-s2.0-0037844594 (Pubitemid 36629135)
55. Pagano G., Cavallo Perin P., Cassader M., An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. Journal of Clinical Investigation 1983 72 5 1814 1820 2-s2.0-0021072412 (Pubitemid 14229061)
56. Abdelmannan D., Tahboub R., Genuth S., Effect of dexamethasone on oral glucose tolerance in normal individuals. Endocrine Practice 2010 16 5 770 777 10.4158/EP09373.OR
57. Nicod N., Giusti V., Besse C., Tappy L., Metabolic adaptations to dexamethasone-induced insulin resistance in healthy volunteers. Obesity Research 2003 11 5 625 631 2-s2.0-4644237871 (Pubitemid 41151613)
58. Dessein P. H., Joffe B. I., Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis and Rheumatism 2006 54 9 2765 2775 2-s2.0-33749323030 10.1002/art.22053 (Pubitemid 44497755)
59. Gremlich S., Roduit R., Thorens B., Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic β cells. Comparison with the effects of fatty acids. The Journal of Biological Chemistry 1997 272 6 3216 3222 2-s2.0-0031033882 10.1074/jbc.272.6.3216 (Pubitemid 27066811)
60. Khan A., Ostenson C. G., Berggren P. O., Efendic S., Glucocorticoid increases glucose cycling and inhibits insulin release in pancreatic islets of ob/ob mice. American Journal of Physiology 1992 263 4 E663 E666 2-s2.0-0026801953
61. Ullrich S., Berchtold S., Ranta F., Seebohm G., Henke G., Lupescu A., Mack A. F., Chao C. M., Su J., Nitschke R., Alexander D., Friedrich B., Wulff P., Kuhl D., Lang F., Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005 54 4 1090 1099 2-s2.0-20144389835 10.2337/diabetes.54.4.1090 (Pubitemid 40446323)
62. Cleeman J. I., Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). The Journal of the American Medical Association 2001 285 19 2486 2497 2-s2.0-0035897696 (Pubitemid 32433843)
63. Bloomgarden Z. T., American association of clinical endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003 26 4 1297 1303 2-s2.0-0042031497 10.2337/diacare.26.4.1297 (Pubitemid 36929287)
64. Balkau B., Charles M. A., Comment on the provisional report from the WHO consultation. European group for the study of insulin resistance (EGIR). Diabetic Medicine 1999 16 5 442 443 10.1046/j.1464-5491.1999.00059.x
65. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
66. Mårin P., Darin N., Amemiya T., Andersson B., Jern S., Bjorntorp P., Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992 41 8 882 886 2-s2.0-0026685047 10.1016/0026-0495(92)90171-6
67. Gill R. S., Sharma A. M., Gill S. S., Birch D. W., Karmali S., The impact of obesity on diabetes mellitus and the role of bariatric surgery. Maturitas 2011 69 2 137 140 2-s2.0-79955977850 10.1016/j.maturitas.2011.03.020
68. Lloyd-Jones D. M., Liu K., Colangelo L. A., Yan L. L., Klein L., Loria C. M., Lewis C. E., Savage P., Consistently stable or decreased body mass index in young adulthood and longitudinal changes in metabolic syndrome components: the coronary artery risk development in young adults study. Circulation 2007 115 8 1004 1011 2-s2.0-33847252897 10.1161/CIRCULATIONAHA.106.648642 (Pubitemid 46328294)
69. Colditz G. A., Willett W. C., Rotnitzky A., Manson J. E., Weight gain as a risk factor for clinical diabetes mellitus in women. Annals of Internal Medicine 1995 122 7 481 486 2-s2.0-0028917432
70. Wing R. R., Bunker C. H., Kuller L. H., Matthews K. A., Insulin, body mass index, and cardiovascular risk factors in premenopausal women. Arteriosclerosis 1989 9 4 479 484 2-s2.0-0024362701 (Pubitemid 19184482)
71. Chan J. M., Rimm E. B., Colditz G. A., Stampfer M. J., Willett W. C., Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994 17 9 961 969 2-s2.0-0027966932 (Pubitemid 24268605)
72. Schienkiewitz A., Schulze M. B., Hoffmann K., Kroke A., Boeing H., Body mass index history and risk of type 2 diabetes: results from the European prospective investigation into cancer and nutrition (EPIC)-potsdam study. American Journal of Clinical Nutrition 2006 84 2 427 433 2-s2.0-33748414239 (Pubitemid 44699156)
73. Cohen S. S., Signorello L. B., Blot W. J., Adult weight gain and diabetes among African American and White adults in southeastern US communities. Preventive Medicine 2009 49 6 476 481 2-s2.0-70649110000 10.1016/j.ypmed.2009. 10.010
74. Nguyen N. T., Magno C. P., Lane K. T., Hinojosa M. W., Lane J. S., Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the national health and nutrition examination survey, 1999 to 2004. Journal of the American College of Surgeons 2008 207 6 928 934 2-s2.0-55949118380 10.1016/j.jamcollsurg.2008.08.022
75. Moon O. R., Kim N. S., Jang S. M., Yoon T. H., Kim S. O., The relationship between body mass index and the prevalence of obesity-related diseases based on the 1995 national health interview survey in Korea. Obesity Reviews 2002 3 3 191 196 2-s2.0-0035990628 10.1046/j.1467-789X.2002.00073.x (Pubitemid 34815238)
76. Rebuffé-Scrive M., Krotkiewski M., Elfverson J., Bjorntorp P., Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism 1988 67 6 1122 1128 2-s2.0-0024271697 (Pubitemid 19012940)
77. Weigensberg M. J., Toledo-Corral C. M., Goran M. I., Association between the metabolic syndrome and serum cortisol in overweight Latino youth. Journal of Clinical Endocrinology and Metabolism 2008 93 4 1372 1378 2-s2.0-42049119855 10.1210/jc.2007-2309 (Pubitemid 351519735)
78. Pasquali R., Cantobelli S., Casimirri F., Capelli M., Bortoluzzi L., Flamia R., Labate A. M. M., Barbara L., The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. Journal of Clinical Endocrinology and Metabolism 1993 77 2 341 346 2-s2.0-0027185253 10.1210/jc.77.2.341 (Pubitemid 23230037)
79. Duclos M., Pereira P. M., Barat P., Gatta B., Roger P., Increased cortisol unavailability, abdominal obesity, and the metabolic syndrome in obese women. Obesity Research 2005 13 7 1157 1166 2-s2.0-33644690146
80. Rebuffé-Scrive M., Walsh U. A., McEwen B., Rodin J., Effect of chronic stress and exogenous glucocorticoids on regional fat distribution and metabolism. Physiology and Behavior 1992 52 3 583 590 2-s2.0-0026649567 10.1016/0031-9384(92)90351-2
81. Epel E. S., McEwen B., Seeman T., Matthews K., Castellazzo G., Brownell K. D., Bell J., Ickovics J. R., Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosomatic Medicine 2000 62 5 623 632 2-s2.0-0033798376
82. Marniemi J., Kronholm E., Aunola S., Toikka T., Mattlar C. E., Koskenvuo M., Rönnemaa T., Visceral fat and psychosocial stress in identical twins discordant for obesity. Journal of Internal Medicine 2002 251 1 35 43 2-s2.0-0036192798 10.1046/j.1365-2796.2002.00921.x (Pubitemid 34209072)
83. Pasquali R., Vicennati V., Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. International Journal of Obesity 2000 24 2 S47 S49 2-s2.0-0033913091 (Pubitemid 30461947)
84. Epel E. S., McEwen B., Seeman T., Matthews K., Castellazzo G., Brownell K. D., Bell J., Ickovics J. R., Stress and body shape: Stress-induced cortisol secretion is consistently greater among women with central fat. Psychosomatic Medicine 2000 62 5 623 632 2-s2.0-0033798376
85. Korbonits M., Trainer P. J., Nelson M. L., Howse I., Kopelman P. G., Besser G. M., Grossman A. B., Svec F., Differential stimulation of cortisol and dehydroepiandrosterone levels by food in obese and normal subjects: relation to body fat distribution. Clinical Endocrinology 1996 45 6 699 706 2-s2.0-0030467287 (Pubitemid 27032315)
86. Vicennati V., Ceroni L., Gagliardi L., Gambineri A., Pasquali R., Response of the hypothalamic pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. Journal of Clinical Endocrinology and Metabolism 2002 87 8 3984 3988 2-s2.0-0035983855 10.1210/jc.87.8.3984 (Pubitemid 34879558)
87. Duclos M., Gatta B., Corcuff J. B., Rashedi M., Pehourcq F., Roger P., Fat distribution in obese women is associated with subtle alterations of the hypothalamic-pituitary-adrenal axis activity and sensitivity to glucocorticoids. Clinical Endocrinology 2001 55 4 447 454 2-s2.0-0034797813 10.1046/j.1365-2265. 2001.01384.x (Pubitemid 32955481)
88. Pasquali R., Anconetani B., Chattat R., Biscotti M., Spinucci G., Casimirri F., Vicennati V., Carcello A., Labate A. M. M., Hypothalamic- pituitary-adrenal axis activity and its relationship to the autonomic nervous system in women with visceral and subcutaneous obesity: effects of the corticotropin-releasing factor/arginine-vasopressin test and of stress. Metabolism 1996 45 3 351 356 2-s2.0-0029881473 10.1016/S0026-0495(96)90290-5 (Pubitemid 26102641)
89. Pasquali R., Vicennati V., The abdominal obesity phenotype and insulin resistance are associated with abnormalities of the hypothalamic-pituitary- adrenal axis in humans. Hormone and Metabolic Research 2000 32 11-12 521 525 2-s2.0-0034473226 (Pubitemid 32176081)
90. Pasquali R., Ambrosi B., Armanini D., Cavagnini F., Uberti E. D., Rio G. D., de Pergola G., Maccario M., Mantero F., Marugo M., Rotella C. M., Vettor R., Cortisol and ACTH response to oral dexamethasone in obesity and effects of sex, body fat distribution, and dexamethasone concentrations: a dose-response study. Journal of Clinical Endocrinology and Metabolism 2002 87 1 166 175 2-s2.0-18244405083 10.1210/jc.87.1.166 (Pubitemid 34084687)
91. Rosmond R., Dallman M. F., Björntorp P., Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. Journal of Clinical Endocrinology and Metabolism 1998 83 6 1853 1859 2-s2.0-0031732443 10.1210/jc.83.6.1853 (Pubitemid 28496305)
92. Vicennati V., Pasqui F., Cavazza C., Garelli S., Casadio E., di Dalmazi G., Pagotto U., Pasquali R., Cortisol, energy intake, and food frequency in overweight/obese women. Nutrition 2011 27 6 677 680 2-s2.0-79955629354 10.1016/j.nut.2010.07.016
93. Anagnostis P., Katsiki N., Adamidou F., Athyros V. G., Karagiannis A., Kita M., Mikhailidis D. P., 11 β -Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders? Metabolism. In press 10.1016/j.metabol.2012.05.002
94. Isomura Y., Mune T., Morita H., Suwa T., Takada N., Yamamoto Y., Takeda J., Physiologic roles of 11 β -hydroxysteroid dehydrogenase type 2 in kidney. Metabolism 2006 55 10 1352 1357 2-s2.0-33748460999 10.1016/j.metabol. 2006.06.005 (Pubitemid 44353553)
95. Walker B., Andrew R., Tissue production of cortisol by 11betahydroxysteroid dehydrogenase type 1 and metabolic disease. Annals of the New York Academy of Sciences 2006 1083 165 184 10.1196/annals.1367.012 (Pubitemid 44955472)
96. Masuzaki H., Paterson J., Shinyama H., Morton N. M., Mullins J. J., Seckl J. R., Flier J. S., A transgenic model of visceral obesity and the metabolic syndrome. Science 2001 294 5549 2166 2170 2-s2.0-0035824440 10.1126/science. 1066285 (Pubitemid 33150673)
97. Wamil M., Seckl J. R., Inhibition of 11 β -hydroxysteroid dehydrogenase type 1 as a promising therapeutic target. Drug Discovery Today 2007 12 13-14 504 520 2-s2.0-34447105433 10.1016/j.drudis.2007.06.001 (Pubitemid 47031664)
98. Masuzaki H., Yamamoto H., Kenyon C. J., Elmquist J. K., Morton N. M., Paterson J. M., Shinyama H., Sharp M. G. F., Fleming S., Mullins J. J., Seckl J. R., Flier J. S., Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. Journal of Clinical Investigation 2003 112 1 83 90 2-s2.0-0041302382 10.1172/JCI200317845 (Pubitemid 38056379)
99. Rosenstock J., Banarer S., Fonseca V. A., Inzucchi S. E., William S., Wenqing Y., Hollis G., Flores R., Levy R., Williams W. V., Seckl J. R., Huber R., The 11- β -hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care 2010 33 7 1516 1522 2-s2.0-77955630861 10.2337/dc09-2315
100. Stewart P., Tissue-specific Cushing's syndrome uncovers a new target in treating the metabolic syndrome-11 β -hydroxysteroid dehydrogenase type 1. Clinical Medicine 2005 5 142 146 (Pubitemid 40593313)
101. Bujalska I., Kumar S., Stewart P., Does central obesity reflect "Cushing's disease of the omentum"? The Lancet 1997 349 9060 1210 1213 10.1016/S0140-6736(96)11222-8 (Pubitemid 27190044)
102. Tahrani A. A., Bailey C. J., Del Prato S., Barnett A. H., Management of type 2 diabetes: new and future developments in treatment. The Lancet 2011 378 9786 182 197 2-s2.0-79960262492 10.1016/S0140-6736(11)60207-9
103. Feig P. U., Shah S., Hermanowski-Vosatka A., Plotkin D., Springer M. S., Donahue S., Thach C., Klein E. J., Lai E., Kaufman K. D., Effects of an 11 β -hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes, Obesity and Metabolism 2011 13 6 498 504 2-s2.0-79955046317 10.1111/j.1463-1326.2011.01375.x
104. Shah S., Hermanowski-Vosatka A., Gibson K., Ruck R. A., Jia G., Zhang J., Hwang P. M. T., Ryan N. W., Langdon R. B., Feig P. U., Efficacy and safety of the selective 11 β -HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. Journal of the American Society of Hypertension 2011 5 3 166 176 2-s2.0-79955639922 10.1016/j.jash.2011.01.009
105. Gibbs J. P., Emery M. G., McCaffery I., Smith B., Gibbs M. A., Akrami A., Rossi J., Paweletz K., Gastonguay M. R., Bautista E., Wang M., Perfetti R., Daniels O., Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11 β -hydroxysteroid dehydrogenase type 1 (11 β -HSD1) activity after oral administration of AMG 221, a selective 11 β -HSD1 Inhibitor. Journal of Clinical Pharmacology 2011 51 6 830 841 2-s2.0-79955865247 10.1177/0091270010374470
106. Chrousos G. P., Is 11 β -hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proceedings of the National Academy of Sciences of the United States of America 2004 101 17 6329 6330 10.1073/pnas.0401671101 (Pubitemid 38585971)
107. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH Consensus and State-of-the-Science Statements 2002 19 2 1 25
108. Reincke M., Subclinical Cushing's syndrome. Endocrinology and Metabolism Clinics of North America 2000 29 1 43 56 2-s2.0-0034017647 (Pubitemid 30151888)
109. Mantero F., Terzolo M., Arnaldi G., Osella G., Masini A. M., Alì A., Giovagnetti M., Opocher G., Angeli A., A survey on adrenal incidentaloma in Italy. Journal of Clinical Endocrinology and Metabolism 2000 85 2 637 644 2-s2.0-0034454579 10.1210/jc.85.2.637 (Pubitemid 32273647)
110. Terzolo M., Pia A., Alì A., Osella G., Reimondo G., Bovio S., Daffara F., Procopio M., Paccotti P., Borretta G., Angeli A., Adrenal incidentaloma: a new cause of the metabolic syndrome? Journal of Clinical Endocrinology and Metabolism 2002 87 3 998 1003 2-s2.0-0036959742 10.1210/jc.87.3.998 (Pubitemid 36121054)
111. Giordano R., Guaraldi F., Berardelli R., Karamouzis I., 'angelo V D., Marinazzo E., Picu A., Ghigo E., Arvat E., Glucose metabolism in patients with subclinical Cushing's syndrome. Endocrine 2012 41 3 415 423 10.1007/s12020-012- 9628-9
112. Mazzuco T. L., Bourdeau I., Lacroix A., Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. Current Opinion in Endocrinology, Diabetes and Obesity 2009 16 3 203 210 2-s2.0-66349131397 10.1097/MED.0b013e32832b7043
113. Morelli V., Masserini B., Salcuni A. S., Eller-Vainicher C., Savoca C., Viti R., Coletti F., Guglielmi G., Battista C., Iorio L., Beck-Peccoz P., Ambrosi B., Arosio M., Scillitani A., Chiodini I., Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clinical Endocrinology 2010 73 2 161 166
114. Rossi R., Tauchmanova L., Luciano A., di Martino M., Battista C., Del Viscovo L., Nuzzo V., Lombardi G., Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features. Journal of Clinical Endocrinology and Metabolism 2000 85 4 1440 1448 2-s2.0-0034456839 10.1210/jc.85.4.1440 (Pubitemid 32289484)
115. Terzolo M., Bovio S., Pia A., Conton P. A., Reimondo G., Dall'Asta C., Bemporad D., Angeli A., Opocher G., Mannelli M., Ambrosi B., Mantero F., Midnight serum cortisol as a marker of increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European Journal of Endocrinology 2005 153 2 307 315 2-s2.0-23844464511 10.1530/eje.1.01959 (Pubitemid 41167489)
116. Tauchmanovà L., Rossi R., Biondi B., Pulcrano M., Nuzzo V., Palmieri E. A., Fazio S., Lombardi G., Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2002 87 11 4872 4878 2-s2.0-0036847434 10.1210/jc.2001-011766 (Pubitemid 35316318)
117. Terzolo M., Bovio S., Reimondo G., Pia A., Osella G., Borretta G., Angeli A., Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinology and Metabolism Clinics of North America 2005 34 2 423 439 2-s2.0-18044380488 10.1016/j.ecl.2005.01.008 (Pubitemid 40602730)
118. Di Dalmazi G., Vicennati V., Rinaldi E., Morselli-Labate A. M., Giampalma E., Mosconi C., Pagotto U., Pasquali R., Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. European Journal of Endocrinology 2012 166 669 677 10.1530/EJE-11-1039
119. Toniato A., Merante-Boschin I., Opocher G., Pelizzo M. R., Schiavi F., Ballotta E., Surgical versus conservative management for subclinical cushing syndrome in adrenal incidentalomas: a prospective randomized study. Annals of Surgery 2009 249 3 388 391 2-s2.0-63449112671 10.1097/SLA.0b013e31819a47d2
120. Giordano R., Marinazzo E., Berardelli R., Picu A., Maccario M., Ghigo E., Arvat E., Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. European Journal of Endocrinology 2010 162 4 779 785 2-s2.0-77950322356 10.1530/EJE-09-0957